Tiered integrated diagnostics for the early detection of aggressive Prostate Cancer: The Riskman-TARGET study to develop a novel screening approach for prostate cancer.
Co-Lead: Mr Vincent J Gnanapragasam, University of Cambridge
Co-Lead: Prof. Kenneth Muir, University of Manchester
Co-Lead: Dr Artitaya (Li) Lophatananon, University of Manchester
University of Manchester: Prof. Gareth Evans, Prof. Martyn Regan
At present, we have an imperfect system where 2 out of 3 men referred for suspected prostate cancer will have unnecessary investigations. The only test currently available to prompt a referral is the PSA test which is not very accurate. Recent research has revealed new knowledge on underlying genetic risk-factors, how the prostate’s natural growth affects PSA and also new markers better for detecting cancer. In this study, we are seeking to combine them in a new step-wise model where men at risk of cancer are first identified from a genetic score. They are then closely monitored using better tests than PSA alone (e.g. correcting PSA for prostate size or use new markers). We will then define a test level, unique to every man, which if breached will trigger a referral. The model will also consider how healthy a man is and whether they are likely to benefit from cancer treatment. If successful, the model (called Riskman-Target), could be used to find men at the highest risk for cancer and monitor them closely. In this way we are more likely to pick up lethal cancers earlier and treat them, conversely many other men will be spared both monitoring and referral.
About ACED Manchester
ACED is a £55 million partnership between world-leading early detection institutes and organisations dedicated to improving the early detection of cancer.